BioPharmSignal logoBioPharmSignal

Biotech News

Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

Erasca (ERAS)ErascaEarnings

Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026 Successfully

Related news

ERASErasca2026-08-11 20:01 EST

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

ERASErasca2026-07-13 20:01 EST

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

ANGOAngioDynamics2026-07-14 10:00 EST

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

ANGOAngioDynamics2026-06-30 12:00 EST

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

MMSIMerit Medical2026-07-30 20:05 EST

Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

View all latest news

Erasca

RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition. ERAS-0015 ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program....

Recent company news

ERASErasca2026-08-24 12:00 EST

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

ERASErasca2026-08-11 20:01 EST

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

ERASErasca2026-08-10 20:01 EST

Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ERASErasca2026-08-10 12:00 EST

Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D

ERASErasca2026-07-15 20:01 EST

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Stock data

Close
17.63 USD
Market cap
4.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States